SCHEDULE: PAVmed Amends Lucid Diagnostics Stake, Bolsters Control
Beneficial Ownership Update
PAVmed Inc. filed an Amendment No. 6 to its Schedule 13D, detailing updated beneficial ownership in Lucid Diagnostics Inc. and new agreements solidifying its influence as the parent company.
Summary
- PAVmed Inc. filed Amendment No. 6 to its Schedule 13D regarding its ownership in Lucid Diagnostics Inc.
- PAVmed Inc. beneficially owns 38,816,903 shares of Lucid Diagnostics Common Stock, representing 27.5% of the class.
- PAVmed Inc. holds significant influence over the election of directors and other matters due to its ownership stake and role as the parent company.
- A new Amendment Agreement, dated February 3, 2026, grants the holder of the 2026 Note the right to receive 300,000 shares of Lucid Diagnostics common stock under specific conditions.
- PAVmed Inc. maintains voting proxies over a total of 7,514,459 votes from various stockholders and officers of Lucid Diagnostics.
- Existing agreements such as the Security and Pledge Agreement, Management Services Agreement (MSA), and Payroll and Benefit Expense Reimbursement Agreement (PBERA) remain in effect, outlining obligations related to the acquisition, transfer, or voting of Common Stock.
- PAVmed Inc. also has voting obligations related to Lucid Diagnostics' convertible notes issued under a Securities Purchase Agreement dated November 12, 2024.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a largely neutral filing, primarily updating regulatory disclosures on beneficial ownership and control. The formalization of agreements reinforces PAVmed's strategic influence over Lucid Diagnostics, which can be seen as a slight positive for stability and alignment, but it doesn't introduce new operational or financial news.
Positives
- PAVmed Inc. has solidified its control and influence over Lucid Diagnostics Inc. through various agreements, including voting proxies and the Amendment Agreement.
- The Amendment Agreement provides a future right for a note holder to receive 300,000 shares, potentially aligning interests.
Future Outlook
PAVmed Inc. intends to continuously review its ownership of Lucid Diagnostics Inc. and may acquire or sell securities based on an ongoing evaluation of Lucid's business, financial condition, operations, prospects, market conditions, and alternative investment opportunities. No present intention to acquire or sell, except as described in Item 6.
Management Comments
- PAVmed Inc. has the power to significantly influence the election of directors and all other matters that would require the vote of the outstanding shares of capital stock of the Issuer.
- The Reporting Person or any of the Principals, respectively, may acquire additional securities of the Issuer and may sell all or a portion of the securities then held in the open market or in privately negotiated transactions, although none of the Reporting Person or the Principals has any present intention to acquire or sell any securities of the Issuer except as described in Item 6.
- Each of the Reporting Person and each of the Principals, respectively, intends to review its ownership of the Issuer on a continuing basis.
Industry Context
StockSavvy.ai notes that this filing reflects a common strategy for parent companies to maintain and formalize control over their subsidiaries, especially in the biotechnology or medical device sectors where strategic alignment and resource allocation are critical. The detailed agreements underscore the importance of governance and financial arrangements between related entities.
Comparison to Industry Standards
- This filing is a standard regulatory disclosure for changes in beneficial ownership and control arrangements. It aligns with typical practices for parent companies like PAVmed Inc. to exert influence over their subsidiaries, such as Lucid Diagnostics Inc., through voting agreements and board representation.
- For instance, similar control mechanisms are observed in other healthcare conglomerates where a larger entity maintains a significant stake and strategic oversight over a specialized subsidiary, ensuring operational and financial synergy. No specific comparable companies or projects are mentioned in the filing to provide a direct numerical comparison.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Control and Influence | PAVmed Inc. has solidified its ability to significantly influence the election of directors and other matters requiring stockholder vote due to its 27.5% beneficial ownership and various voting agreements. | 2026-02-03 | Enhances PAVmed's strategic oversight and control over Lucid Diagnostics, potentially leading to greater operational alignment and resource allocation decisions. |
| Shareholder Rights/Agreements | An Amendment Agreement grants the holder of the 2026 Note the right to receive 300,000 shares of Lucid Diagnostics common stock under specific conditions. | 2026-02-03 | Introduces a future equity transfer mechanism tied to the 2026 Note, potentially impacting future share dilution and aligning interests with a key debt holder. |
| Voting Arrangements | PAVmed Inc. has secured additional voting proxies from a stockholder (3,177,500 Common Stock votes and 4,063,286 other capital stock votes) and previously from officers (4,336,959 Common Stock votes). | 2025-10-09 | Strengthens PAVmed's voting power and ability to direct corporate actions and board composition at Lucid Diagnostics. |
Related Party Transactions
- PAVmed Inc. is the parent company of Lucid Diagnostics Inc.
- PAVmed Inc. has a Management Services Agreement (MSA) and a Payroll and Benefit Expense Reimbursement Agreement (PBERA) with Lucid Diagnostics Inc.
- Certain officers and directors of PAVmed Inc. (Principals) also hold restricted stock and/or stock option awards from Lucid Diagnostics Inc.
- PAVmed Inc. entered into an Amendment Agreement with the holder of the 2026 Note, which is a senior secured convertible promissory note issued by the Reporting Person.
Stakeholder Impact
- Shareholders (Lucid Diagnostics): PAVmed's increased formal control could lead to more stable strategic direction but also potentially limit independent decision-making by Lucid's minority shareholders. The future issuance of 300,000 shares could cause minor dilution.
- Creditors (2026 Note Holder): The Amendment Agreement provides a clear path for the note holder to receive equity, potentially enhancing the value of their investment if Lucid's stock performs well.
- Management/Employees (Lucid Diagnostics): The strong parent company oversight might influence operational autonomy and strategic initiatives. Compensation for certain principals includes Lucid Diagnostics equity.
Next Steps
- PAVmed Inc. and its Principals will continue to review their ownership of Lucid Diagnostics Inc. on an ongoing basis.
- The holder of the 2026 Note may receive 300,000 shares of Lucid Diagnostics common stock upon the earliest of February 3, 2029, the date the 2026 Note is no longer outstanding, or an earlier notification from PAVmed Inc.
Key Dates
| Date | Description |
|---|---|
| 2018-05-12 | Original date of the Management Services Agreement (MSA) with the Issuer. |
| 2021-10-27 | Original filing date of the Schedule 13D. |
| 2022-04-04 | Date of the Security and Pledge Agreement with the Holder. |
| 2022-11-30 | Original date of the Payroll and Benefit Expense Reimbursement Agreement (PBERA) with the Issuer. |
| 2022-12-02 | Date of a previous amendment to the Schedule 13D. |
| 2024-02-02 | Date of a previous amendment to the Schedule 13D. |
| 2024-02-20 | Date of a previous amendment to the Schedule 13D. |
| 2024-11-12 | Date of the Securities Purchase Agreement (Issuer Note SPA) for the sale of convertible notes by the Issuer. |
| 2024-12-12 | Date of a previous amendment (Amendment No. 4) to the Schedule 13D. |
| 2025-03-24 | Filing date of the Issuer's Annual Report on Form 10-K, which describes the MSA and PBERA. |
| 2025-10-09 | Date of a Voting Agreement with a stockholder of the Issuer. |
| 2025-10-10 | Date of a previous amendment to the Schedule 13D. |
| 2026-02-03 | Date of the Amendment Agreement with the holder of the 2026 Note, and the date of the event requiring this filing. |
| 2026-02-09 | Filing date of this Amendment No. 6 to Schedule 13D. |
| 2029-02-03 | Maturity date of the 2026 Note, upon which the Holder may receive 300,000 shares of Issuer's common stock. |
Recommendation
holdThis filing primarily updates regulatory disclosures regarding beneficial ownership and control, reinforcing PAVmed's existing influence over Lucid Diagnostics. It does not present new financial performance data, significant strategic shifts, or operational catalysts that would warrant a 'buy' or 'sell' recommendation. The formalization of control provides stability but no immediate growth drivers. Therefore, a 'hold' recommendation is appropriate for investors to await further operational or financial updates.
Keywords
PAVmed Inc., Lucid Diagnostics Inc., Schedule 13D/A, beneficial ownership, voting power, corporate control, parent company, common stock, convertible note, voting agreement, SEC filing, corporate governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.